Abstract
Introduction
In 2008, seven major market sales of antipsychotics reached $18.2 billion.
Datamonitor forecasts the market value to peak in 2011 when it will then
succumb to generic erosion, particularly in the US where incursion is the most
rapid. However, the commercial opportunity still exists for developers who can
differentiate their antipsychotics with reformulation and indication expansion
strategies.
Scope of this research
- In-depth analysis of the current and future antipsychotic drug class
market across the US, Japan, France, Germany, Italy, Spain and the UK.
- Country-specific total brand sales forecasts for key products, generics
and pipeline agents across the seven major markets to 2018.
- Assessment and appreciation of the numerous opportunities and threats
present in the antipsychotic market, with analysis of emerging markets trends.
- Case study evaluation of the strategies employed by key players in the
antipsychotic market, including Johnson & Johnson, AstraZeneca and Eli Lilly.
Research and analysis highlights
Due to a high rate of generic incursion, the US market value is expected to
decline over the forecast period (20092018). As the US accounts for around 75%
of the total 2008 seven major market value, this decline will counteract
positive growth anticipated in the other regions, including Europe and Japan.
The launch of the once-monthly dosed depot formulations, Zypadhera (olanzapine
pamoate; Eli Lilly) and Invega Sustenna (paliperidone palmitate; Johnson &
Johnson), will seek to address widespread compliance issues in schizophrenia
patients and provide protection to marketing companies' respective franchises.
Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka) will emerge as the market
leading brand in 2012. At this point, other major brands will be facing
generic competition. Given its innovative mode of action, strong efficacy and
favorable side-effect profile, Abilify will be sufficiently differentiated to
avoid major indirect generic competition.
Key reasons to purchase this research
- Quantify the current and future size of the antipsychotic drug class
market.
- Assess the impact of recent and anticipated events (patent expiries and
new product launches) on the antipsychotic drug class market.
- Understand the country-specific impact of key events in the antipsychotic
drug class market during the forecast period 2009 to 2018.
| 
View Cart
